To assess whether inhibition of the NF-κB canonical pathway was associated with concomitant suppression of glycolysis in HCC, HepG2.2.15 and Hep3B cells were treated with Bay 11–7082 (an inhibitor of NF-κB). Here, NFKB1 is linked to hepatocellular carcinoma.